- Home
- NTRS vs ONC Comparison
NTRS vs ONC Comparison
Compare NTRS & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NTRS | ONC |
|---|---|---|
| Founded | 1889 | 2010 |
| Country | United States | Switzerland |
| Employees | 23800 | 12000 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1B | 31.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRS | ONC |
|---|---|---|
| Price | $172.34 | $269.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $163.55 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 950.5K | 259.3K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.40 | $723.76 |
| Revenue Next Year | $4.13 | $15.04 |
| P/E Ratio | ★ $16.88 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $118.99 | $239.25 |
| 52 Week High | $176.99 | $385.22 |
Technical Indicators
Market Signals| Indicator | NTRS | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 41.48 |
| Support Level | $165.90 | $253.95 |
| Resistance Level | $172.36 | $323.73 |
| Average True Range (ATR) | 4.03 | 7.22 |
| MACD | 0.06 | -0.25 |
| Stochastic Oscillator | 62.31 | 49.60 |
Price Performance
Historical ComparisonAbout NTRS Northern Trust Corporation
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.